MNPR logo

MNPR
Monopar Therapeutics Inc

3,308
Mkt Cap
$419.9M
Volume
57,641.00
52W High
$105.00
52W Low
$28.40
PE Ratio
-30.33
MNPR Fundamentals
Price
$63.09
Prev Close
$62.68
Open
$62.23
50D MA
$57.06
Beta
1.48
Avg. Volume
171,499.83
EPS (Annual)
-$1.85
P/B
3.10
Rev/Employee
$0.00
$343.70
Loading...
Loading...
News
all
press releases
MNPR Stock Rallies After Hours As Experimental Drug Shows Rapid Copper Balance Improvement In Genetic Disorder
The open-label trial showed the drug helped the body remove excess copper more effectively and quickly, mainly by increasing copper excretion through stool.
News Placeholder
More News
News Placeholder
Monopar Therapeutics (MNPR) Expected to Announce Earnings on Tuesday
Monopar Therapeutics (NASDAQ:MNPR) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-monopar-therapeutics-inc-stock...
News Placeholder
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages
Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have earned a consensus recommendation of "Buy" from the thirteen research firms that are presently covering the stock, MarketBeat...
News Placeholder
Monopar Therapeutics (NASDAQ:MNPR) Lowered to Strong Sell Rating by Wall Street Zen
Wall Street Zen downgraded Monopar Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday...
News Placeholder
Brookline Capital Markets Forecasts MNPR Q1 Earnings
Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at Brookline Capital Markets increased their Q1 2026 EPS estimates for Monopar Therapeutics in a research report...
News Placeholder
HC Wainwright Brokers Reduce Earnings Estimates for MNPR
Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at HC Wainwright lowered their Q1 2026 EPS estimates for Monopar Therapeutics in a report issued on Monday, March 30th. HC...
News Placeholder
Chardan Capital Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR)
Chardan Capital reaffirmed a "buy" rating and issued a $100.00 price target on shares of Monopar Therapeutics in a research note on Monday...
News Placeholder
Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) announced its earnings results on Friday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of...
News Placeholder
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Buy" from Analysts
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) has been given a consensus rating of "Buy" by the thirteen analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have given a buy rating and two have is...
News Placeholder
Monopar Therapeutics (MNPR) to Release Earnings on Monday
Monopar Therapeutics (NASDAQ:MNPR) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-monopar-therapeutics-inc-stock...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available